Tuesday, October 4, 2022

561.316.3330

Biotechnology News Magazine

Antev Appoints Dr Steven van Os as Chief Medical Officer

Latest Posts

BRAINBox Solutions Announces New U.S. Patent Allowance, Strengthening Biomarker Portfolio for Multi-Modal Mild Traumatic Brain Injury Test

BRAINBox Solutions notes the new patent covers both diagnosis of TBI and patient monitoring post-injury, particularly for determining return to work or play.

New Initiative Brings Leading Life Sciences Companies Together To Drive Collective Impact in Awareness, Diagnosis, Care, and Health Equity for Patients with Amyloidosis

Despite notable progress in recent years, amyloidosis patients continue to experience high unmet needs and gaps in treatment and support.

GBS Inc. Acquires Intelligent Fingerprinting Limited and its Proprietary Drugs of Abuse Screening Technology

Steven Boyages, CEO of GBS Inc. stated, “We believe this acquisition generates significant value for our shareholders, and I am extremely excited to be on the forefront of this transition. Bringing IFP under the GBS umbrella marks a significant advancement toward achieving our strategic goals of improving patients’ lives outside of saliva-based glucose testing and laying the pathway in becoming a leader in the development of rapid, non-invasive diagnostic solutions. We remain excited to accelerate our strategy and revenue growth through this collaboration with IFP.”

Araris Biotech Closes $24 Million Financing Round

Araris Biotech notes the proceeds from the financing will be used to support the further development and advancement of Araris’ antibody-drug conjugate (ADC) candidates, created using the Company’s proprietary linker technology, as Araris moves closer toward clinical development.

Dr Steven van Os joins the executive management team with responsibility for the development of the company´s clinical portfolio in men’s health. 

Dr Steven van Os has successfully led clinical development, medical affairs and regulatory approval for drugs across several therapy areas including Oncology, Urology, Hepatology and Gynaecology.  He has been associated with regulatory approvals across FDA, EMA and several other markets over an impressive career spanning more than 30 years. 

“We are delighted to welcome Steve to Antev as Chief Medical Officer at this exciting and critical stage in Antev’s journey to secure regulatory approval for teverelix in Advanced Prostate Cancer and further indications”, commented Amit Kohli, Chief Executive Officer of Antev. “With compelling efficacy and safety data in the ongoing study in Advanced Prostate Cancer patients and strong support of leading scientific thought leaders, Steve’s relevant experience will ensure that the patients will have access to teverelix as soon as possible.”

 

Antev’s new Chief Medical Officer, Dr Steve van Os, added, “Having worked in the past on the development and registration of Xtandi for prostate cancer patients, I am now thrilled to join Antev, an agile biotech company that is developing a novel GnRH antagonist, designed to deliver improved compliance and outcomes, as a potential life-saving treatment for patients with hormone sensitive advanced prostate cancer.  Working with Antev’s highly experienced team I look forward to bringing teverelix to its full potential for the treatment of prostate cancer”.

 

Dr van Os is a qualified medical doctor, who received his undergraduate training and his M.D. from the University of Utrecht, Netherlands.  Before joining industry in 1997, Dr Van Os was a practicing physician at Hofpoort Hospital, Woerden and at Avios Health Services.

Since then he has held senior leadership roles in a number of large pharmaceutical companies, including Astellas Pharma, Schering Plough, Organon International and Yamanouchi Europe.  He has been involved in multiple product approvals. Most recently as co-chair of the Pfizer/ Astellas alliance, he led the global development and approval of the prostate cancer drug, Xtandi into 97 countries. 

 

He is currently a member of the Netherlands Association of Pharmaceutical Physicians and is a member of the Dutch Board for Pharmaceutical Medicine.


Other executives on the move can be found here.

Latest Posts

Learn More

spot_img

Subscribe

spot_img

Our Sister Publication

Medical Device News Magazine